[e-farmacos] WHO Pharmaceuticals Newsletter No. 4, 2007

["Canas, Martin" <macanas@netverk.com.ar>]

Estimadas y estimados,

Salio el WHO Pharmaceuticals Newsletter No. 4, 2007

con el siguiente contenido:

Regulatory Matters
Ceftriaxone: Some deaths due to calcium-ceftriaxone precitpitates 1
Cinacalcet: Labelling updated for restrictions in use 1
Edaravone: Report of fulminant hepatitis 1
Piroxicam: Restrictions in use 1
Rimonabant: Contraindicated in patients with major depression 2
Tegaserod: Suspended in China; withdrawn in Switzerland; permitted for
restricted use in the USA 2
Thiazolidinedione antidiabetics: Boxed warning on label about heart failure
risk 3
Warfarin: Label to explain influence of genetic makeup on drug response 3
Safety of Medicines
Colistemethate: Premixed formulations must be administered promptly 4
Fluidione, pentoxyfylline: Same trade name caused serious medication error;
need to promote use
of INNs 4
Non-prescription cough and cold medicines: Caution needed with use in
children 5
Norethisterone: Reports of decreased lactation 5
Propofol: Reports of chills, fevers, body aches 5
Rituximab: Reports of progressive multifocal leukoencephalopathy (PML) 6
Salbutamol sulfate for injection: Myocardial ischemia in pregnancy 6
Feature
How to classify drugs and measure drug consumption - a course in the ATC/DDD
methodology 7
Sixteenth Meeting of the Global Advisory Committee on Vaccine Safety, 12-13
June, 2007, Geneva 9

Proximamente disponible en:
http://www.who.int/medicines/publications/newsletter/en/index.html

Saludos,

Martin

Martin Canas
GAPURMED
La Plata
(Argentina)
macanas@netverk.com.ar